[Event Report] Roundtable on Medical Fee System Measures to Discourage the Spread of AMR (September 28, 2020)
date : 11/5/2020
Tags: AMR
AMR Alliance Japan (Secretariat: Health and Global Policy Institute (HGPI)) held a Roundtable on Medical Fee System Measures to Discourage the Spread of AMR.
This meeting was held on the basis of AMR Alliance Japan’s overarching policy recommendations published in July 2019 which called for the promotion of measures through the medical fee system to incentivize behaviors that could help to discourage the spread of antimicrobial resistance (AMR).
AMR Alliance Japan members discussed recommendations toward the 2022 revision of the medical fee system. Based on the discussion, AMR Alliance Japan decided on the key items to be targeted in future proposals on the medical fee system revision.
In light of the situation with novel coronavirus, this meeting was carried out primarily online.
■Overview
Date and time: Wednesday, September 28, 2020
Organizer: AMR Alliance Japan (Secretariat: HGPI)
■Program
Roundtable Discussion
・Key items for AMR Alliance Japan’s Medical Fee System Revision Proposal
・Future Plans
■Roundtable Speakers (alphabetical order by last name):
Kazuyuki Akai (Director, Business Development, Nippon Becton Dickinson Company Ltd.)
Midori Hirai (Chair, Pharmaceutical Education Committee, The Pharmaceutical Society of Japan / Director, Japanese Red Cross Hyogo Blood Center)
Masashi Kawata (Senior Manager, Public Affairs & Policy, Corporate Affairs, Health & Value, Pfizer Japan Inc.)
Takashi Kitahara (Chairman, Japan Pharmaceutical Association / Professor, Department of Clinical Pharmacology, Yamaguchi University)
Yuri Miura (Senior Industry Policy Specialist, Public and Industrial Policy, Health Policy, MSD K.K.)
Masaaki Miyakawa (Executive Board Member, Japan Medical Association)
Choichiro Miyazaki (Vice Chairman, Japan Pharmaceutical Association)
Yuichi Muraki (Representative, Japanese Society of Pharmaceutical Health Care and Sciences / Professor, Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University)
Akio Ozaki (Director, Public and Industry Policy, Health Policy, MSD K. K.)
Toshiyuki Sakaeda (President, The Japanese Society of Therapeutic Drug Monitoring / Professor, Department of Pharmacokinetics, Kyoto Pharmaceutical University)
Makoto Seno (Marketing Director, Nippon Becton Dickinson Company Ltd.)
Kazutoshi Shibuya (President, The Japanese Society for Medical Mycology / Professor, Department of Surgical Pathology, Toho University)
Kazuhiro Tateda (President, The Japanese Association for Infectious Diseases / President, The Japanese Society for Clinical Microbiology / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Yasunori Tawaragi (Director, International Affairs, Japan Pharmaceutical Manufacturers Association)
■Moderator:
Yuki Awano (AMR Alliance Japan Secretariat / Associate, HGPI)
Top Research & Recommendations Posts
- [Policy Recommendations] Integrating Climate and Health for a Sustainable Society: Incorporating a Planetary Health Perspective into Nationally Determined Contributions (NDCs)(December 9, 2024)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Research Report] Survey of Japanese Nursing Professionals Regarding Climate Change and Health (Final Version) (November 14, 2024)
- [Announcement] A Turning Point Towards Building Green Healthcare Systems (June 5, 2024)
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Event Report] Planetary Health Expert Meeting Aiming for Sustainable Healthcare: Learning from the Impact of Environmental Pollution and Medical Waste During the Pandemic (February 16, 2024)
- [Policy Recommendations] Achieving a Sustainable Society of Health and Longevity Through the Integration of Environment and Healthcare-Incorporating a Planetary Health Perspective into the 3rd Phase of The Healthcare Policy-(December 20, 2024)
- [Policy Recommendations] Policy Recommendations on Strengthening CKD Strategies for Workers: The Importance of Providing Early Detection, Intervention, and Support Through Screenings and Medical Visits (October 28, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
Featured Posts
-
2024-11-25
[Registration Open] (Webinar) The 130th HGPI Seminar “Marking a Decade of the Act on Medical Care for Patients With Intractable Diseases: Connecting Intractable Diseases and Society From the Perspective of a Media Professional and Family Member” (January 28, 2025)
-
2024-12-09
[Policy Recommendations] Integrating Climate and Health for a Sustainable Society: Incorporating a Planetary Health Perspective into Nationally Determined Contributions (NDCs)(December 9, 2024)
-
2024-12-12
[HGPI Policy Column] (No. 51) From the Planetary Health Project “Part 11: Efforts Toward Achieving Carbon Neutrality in Japan’s Pharmaceutical Industry”
-
2024-12-18
[Policy Recommendations] Policy Recommendations on Strengthening CKD Strategies for Workers: The Importance of Providing Early Detection, Intervention, and Support Through Screenings and Medical Visits (October 28, 2024)
-
2024-12-25
[Registration Open] (Hybrid Format) Expert Meeting “Innovations Required to Achieve Precision Psychiatry“ (January 22, 2025)